Plain-English translation of NCT07067268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether tislelizumab combined with capecitabine can help treat nasopharyngeal cancer (a type of throat cancer) in people who finished radiation therapy but still have detectable Epstein-Barr virus in their blood. The study will compare people who receive this medication combination with people who only receive regular monitoring. Researchers want to see if the medication can prevent the cancer from coming back.
Some people with throat cancer continue to have signs of Epstein-Barr virus even after completing radiation therapy, which can mean a higher risk of cancer returning. This trial is exploring whether adding this medication after radiation might help eliminate those remaining signs and improve long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive the medication combination (tislelizumab and capecitabine) or to receive only regular follow-up monitoring. If assigned to the treatment group, you would take the medication as directed and attend visits for safety checks, blood tests, and imaging scans to monitor your progress. The study involves about 76 people total and will track how well the medication works and any side effects you may experience.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~76 participants
Started
September 2024
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hongmei Ying
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.